Search Results - "ANDREUCCETTI, Michele"

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest by FALCONE, Alfredo, RICCI, Sergio, CORTESI, Enrico, PICONE, Vincenzo, VITELLO, Stefano, CHIARA, Silvana, GRANETTO, Cristina, PORCILE, Gianfranco, FIORETTO, Luisa, ORLANDINI, Cinzia, ANDREUCCETTI, Michele, MASI, Gianluca, BRUNETTI, Isa, PFANNER, Elisabetta, ALLEGRINI, Giacomo, BARBARA, Cecilia, CRINO, Lucio, BENEDETTI, Giovanni, EVANGELISTA, Walter, FANCHINI, Laura

“…The Gruppo Oncologico Nord Ovest (GONO) conducted a phase III study comparing fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI [irinotecan 165…”
Get full text

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial by Masi, Gianluca, Dr, Loupakis, Fotios, MD, Salvatore, Lisa, MD, Fornaro, Lorenzo, MD, Cremolini, Chiara, MD, Cupini, Samanta, MD, Ciarlo, Andrea, MD, Del Monte, Francesca, PhD, Cortesi, Enrico, MD, Amoroso, Domenico, MD, Granetto, Cristina, MD, Fontanini, Gabriella, Prof, Sensi, Elisa, MD, Lupi, Cristiana, MD, Andreuccetti, Michele, CTA, Falcone, Alfredo, MD

“…Summary Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil,…”
Get full text

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases by MASI, Gianluca, LOUPAKIS, Fotios, PIETRABISSA, Andrea, GOLETTI, Orlando, BALDI, Giacomo, FORNARO, Lorenzo, ANDREUCCETTI, Michele, FALCONE, Alfredo, POLLINA, Luca, VASILE, Enrico, CUPINI, Samanta, RICCI, Sergio, BRUNETTI, Isa Maura, FERRALDESCHI, Roberta, NASO, Giuseppe, FILIPPONI, Franco

“…The GONO-FOLFOXIRI regimen improved the rate of R0 secondary resection of metastases in initially unresectable metastatic colorectal cancer. The objective of…”
Get full text

Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study by Zustovich, Fable, Landi, Lorenza, Lombardi, Giuseppe, Porta, Camillo, Galli, Luca, Fontana, Andrea, Amoroso, Domenico, Galli, Costanza, Andreuccetti, Michele, Falcone, Alfredo, Zagonel, Vittorina

“…Bevacizumab has provided encouraging results in relapsed glioblastoma multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous…”
Get full text

Localization of a GSH-Dependent Dehydroascorbate Reductase in Rat Tissues and Subcellular Fractions by Paolicchi, Aldo, Pezzini, Angelina, Saviozzi, Michela, Piaggi, Simona, Andreuccetti, Michele, Chieli, Elisabetta, Malvaldi, Gino, Casini, Alessandro F.

“…A novel GSH-dependent dehydroascorbate (DHA) reductase from rat liver cytosol has been recently purified and partially characterized in our laboratory. A…”
Get full text

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis by MASI, Gianluca, VASILE, Enrico, FABBRI, Maria Agnese, PUGLISI, Martina, TRENTA, Patrizia, GRANETTO, Cristina, CHIARA, Silvana, FIORETTO, Luisa, ALLEGRINI, Giacomo, CRINO, Lucio, ANDREUCCETTI, Michele, FALCONE, Alfredo, LOUPAKIS, Fotios, CUPINI, Samanta, FORNARO, Lorenzo, BALDI, Giacomo, SALVATORE, Lisa, CREMOLINI, Chiara, STASI, Irene, BRUNETTI, Isa

“…In a randomized trial with a median follow-up of 18.4 months, 6 months of induction chemotherapy with a three-drug regimen comprising 5-fluorouracil (by…”
Get full text

Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All by Caponi, Sara, Vasile, Enrico, Ginocchi, Laura, Tibaldi, Carmelo, Borghi, Francesca, D’Incecco, Armida, Lucchesi, Maurizio, Caparello, Chiara, Andreuccetti, Michele, Falconel, Alfredo

“…Abstract After progression following first-line treatment, many patients with advanced non–small-cell lung cancer (NSCLC) still have a good performance status…”
Get full text

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma by Loupakis, Fotios, Masi, Gianluca, Fornaro, Lorenzo, Vasile, Enrico, Allegrini, Giacomo, Fontana, Eloise, Granetto, Cristina, Salvatore, Lisa, Mentuccia, Lucia, Andreuccetti, Michele, Cortesi, Enrico, Merlano, Marco, Cascinu, Stefano, Falcone, Alfredo

“…Purpose 5-Fluorouracil (5-FU) plus cisplatin (C) can be considered a standard option for advanced gastric cancer (AGC). Irinotecan (Ir) and docetaxel (D) are…”
Get full text